HDAC-IN-52

Cat. No.:	HY-152174
CAS No.:	2075787-77-6
Molecular Formula:	$C_{24}H_{20}N_4O_2$
Molecular Weight:	396.44
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HDAC-IN-52 is a pyridine-containing HDAC inhibitor, with IC_{50}s of 0.189, 0.227, 0.440 and 0.446 μM for HDAC1, HDAC2, HDAC3 , and HDAC10, respectively. HDAC-IN-52 can be used for the research of cancer[1].			
IC_{50} & Target	hHDAC1 0.189 μM (IC_{50})	hHDAC2 0.227 μM (IC_{50})	hHDAC3 0.440 μM (IC_{50})	hHDAC10 0.446 μM (IC_{50})
In Vitro	HDAC-IN-52 (compound 8f) (72 hours) inhibits the proliferation of HCT116, A549 and K562 cells, with IC_{50}s of 0.43, 1.28, and 0.37 μM, respectively[1]. HDAC-IN-52 (1-5 μM; 24-48 h) induces remarkable leukaemia U937 cell death after 48 h, with 76% and 100% pre-G1 phase arrest, respectively[1]. HDAC-IN-52 (1-5 μM; 48 h) increases mRNA expression of p21, BAX and BAK, downregulated cyclin D1 and BCL-2[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Bello ED, et, al. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells. Eur J Med Chem. 2022 Dec 15;247:115022.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA